AST-120 (Kremezin®) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects

Diabetes Research and Clinical Practice

Volumn 81, Issue 3, 2008, Pages 310-315

  Konishi, Kazunori ^a   Nakano, Shigeru ^a   Tsuda, Shin ichi ^a   Nakagawa, Atsushi ^a   Kigoshi, Toshikazu ^a   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

AST 120; Early stage renal failure; Prospective study; Serum creatinine; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AST 120; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDICAN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; BLOOD PRESSURE; CARBON; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; OXIDES; PATIENT SELECTION; PROSPECTIVE STUDIES;

EID: 48949090236     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.04.024     Document Type: Article

References (20)

1. Sanaka T., Akizawa T., Koide K., and Koshikawa S. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Ther. Apher. Dial. 8 (2004) 232-240
2. Shimizu H., Okada S., Shinsuke O., and Mori M. Kremezin (AST-120) delays the progression of diabetic nephropathy in Japanese type 2 diabetic patients. Diabetes Care 28 (2005) 2590
3. Nakamura T., Ueda Y., Kawagoe Y., Ebihara I., and Koide H. Effects of oral adsorbent AST-120 in patients with chronic renal failure with or without diabetes. Renal Fail. 26 (2004) 99-101
4. Owada A., Nakao M., Koike J., Ujiie K., Tomita K., and Shiigai T. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int. 52 (1997) S188-S190
5. Schulman G., Agarwal R., Acharya M., Berl T., Blumenthal S., and Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am. J. Kidney Dis. 47 (2006) 565-577
6. Niwa T., Tsukushi S., Ise M., Miyazaki T., Tsubakihara Y., Owada A., et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner. Electrolyte Metab. 23 (1997) 179-184
7. Okada K., Shibahara H., and Takahashi S. Effect of oral adsorbent on the progression of diabetic nephropathy. Nephron 76 (1997) 489-490
8. ®) on renal function and glomerular injury in early-stage renal failure of subtotal nephrectomized rats. Nephron 91 (2002) 480-485
9. Shoji T., Wada A., Inoue K., Hayashi D., Tomida K., Furumatsu Y., et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin. Pract. 105 (2007) c99-c107
10. Ueda H., Shibahara N., Takagi S., Inoue T., and Katsuoka Y. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther. Apher. Dial. 11 (2007) 189-195
11. Nakano S., Fukuda M., Hotta F., Ito T., Ishii T., Kitazawa M., et al. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 47 (1998) 1501-1506
12. Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145 (2006) 247-254
13. Imai E., and Horio M. Epidemiology of chronic kidney disease: the difference between Japan and Western countries. J. Blood Press. 13 (2006) 359-363 (in Japanese)
14. Yorioka N., Ito T., Masaki T., Ogata S., Asakimori Y., Tanji C., et al. Dose-dependent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure. J. Int. Med. Res. 30 (2002) 467-475
15. Anavekar N.S., McMurray J.J.V., Velazquez E.J., Solomon S.D., Kober L., Rouleau J.-L., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardiac infarction. N. Engl. J. Med. 351 (2004) 1285-1295
16. Go A.S., Chertow G.M., Fan D., Hsu C.E., and McCulloch C. Chronic kidney disease and risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351 (2004) 1296-1305
17. Nakamura T., Kawagoe Y., Matsuda T., Ueda Y., Shimada N., Ebihara I., et al. Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press. Res. 27 (2004) 121-126
18. Yamagishi S., Nakamura K., Matsui T., Inoue H., and Takeuchi M. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Med. Hypotheses 69 (2007) 666-668
19. Vlassara H., Cai W., Crandall J., Goldberg T., Oberstein R., Dardaine V., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15596-15601
20. Ueda S., Yamagishi S., Takeuchi M., Kohno K., Shibuta R., Matsumoto Y., et al. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol. Med. 12 (2006) 180-184